Sequential Administration of Human and Porcine Factor VIII for Surgical Treatment of a Parotid Tumour in a Patient with a Factor VIII Inhibitor

Briët, E.; Meer, F.W. van der; Kempen, C.J.M. van Dijk-van; Schmidt, Petra; Otten, F.W.A.; Meyer, K A

doi:10.1159/000206289

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The purifica tion procedure of porcine factor VIII has been improved since 1980 by using ion exchange chromatography with polyelectrolytes [6] (Hyate:C®, Porton Products, UK). This new concentrate has been extensively used in the UK [7], Italy [8,9], the USA [10] and elsewhere [11,12], It has even been used for home therapy and the induction of immune tolerance in a small number of patients [13].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Anti-Human and Anti-Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

Fiks-Sigaud¹,

Bendelac²,

Parquet³

et al. 1993

Vox Sanguinis

View full text Add to dashboard Cite

The levels of anti-human and anti-porcine factor VIII inhibitors, measured in 63 severe haemophilia A patients, lay in the ranges of <0.2-2,600 and <0.2-1,300 Bethesda units per ml (BU/ml), respectively, with a median cross-reactivity of 33%. In 4 patients, human and porcine inhibitor levels were determined using both plasma, either human or porcine, and factor VIII concentrate, either very high purity human or porcine (Hyate:C®). A good correlation between titres was found, whatever the source of factor VIII (plasma or concentrate). The cross-reactivity varies from 0 to over 100%, indicating that the evaluation of both human and porcine inhibitors should be mandatory before any treatment with Hyate:C. Results show that of the 46 patients with human inhibitor of more than 5 BU/ml, 21 (46%) with a low porcine inhibitor (<5 BU/ml) could benefit from Hyate:C.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Anti-Human and Anti-Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

Fiks-Sigaud¹,

Bendelac²,

Parquet³

et al. 1993

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Les inhibiteurs spontanés du facteur antihémophilique A : Données cliniques et biologiques, aspects thérapeutiques

Staïkowsky

Guidet

Thuaire

1992

Réanimation Urgences

View full text Add to dashboard Cite

Comparison of Anti-Human and Anti-Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

Fiks-Sigaud¹,

Bendelac²,

Parquet³

et al. 1993

Vox Sanguinis

View full text Add to dashboard Cite

The levels of anti-human and anti-porcine factor VIII inhibitors, measured in 63 severe haemophilia A patients, lay in the ranges of < 0.2-2,600 and < 0.2-1,300 Bethesda units per ml (BU/ml), respectively, with a median cross-reactivity of 33%. In 4 patients, human and porcine inhibitor levels were determined using both plasma, either human or porcine, and factor VIII concentrate, either very high purity human or porcine (Hyate:C). A good correlation between titres was found, whatever the source of factor VIII (plasma or concentrate). The cross-reactivity varies from 0 to over 100%, indicating that the evaluation of both human and porcine inhibitors should be mandatory before any treatment with Hyate:C. Results show that of the 46 patients with human inhibitor of more than 5 BU/ml, 21 (46%) with a low porcine inhibitor (< 5 BU/ml) could benefit from Hyate:C.

show abstract

Sequential Administration of Human and Porcine Factor VIII for Surgical Treatment of a Parotid Tumour in a Patient with a Factor VIII Inhibitor

Cited by 5 publications

References 5 publications

Comparison of Anti-Human and Anti-Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

Comparison of Anti-Human and Anti-Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

Les inhibiteurs spontanés du facteur antihémophilique A : Données cliniques et biologiques, aspects thérapeutiques

Comparison of Anti-Human and Anti-Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

Contact Info

Product

Resources

About